...presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco in September. Novacta Biosystems Ltd....

...Novacta began a Phase I trial to evaluate oral NVB302 in healthy volunteers. Novacta Biosystems Ltd. , Welwyn...

...LSE:SLN), London, U.K. Business: Cancer, Renal, Ophthalmic Hired: Tony Sedgwick as CBO, formerly CEO of Novacta Biosystems Ltd....

...in an equity financing led by new investor Celtic Pharma. Undisclosed existing investors also participated. Novacta's...
...class of antibiotic peptide found in bacteria. Celtic's Richard Garraway and Bob Milsted will join Novacta's...

...the first fund. The firm was to announce it will acquire a 60% stake in Novacta Biosystems Ltd....
...on and dealt with accordingly," he said. Celtic would always expect to have board representation. Novacta...

...steps could include further optimization of the mutagenesis methodology to produce more potent lead compounds. Novacta...
...unavailable Appleyard, A. et al. Cell; published online May 28, 2009; doi:10.1016/j.chembiol.2009.03.011 Contact: Jesus Cortes, Novacta...

...The ministry will evaluate Novacta's lantibiotics for antiviral use. Novacta's Novacta Therapeutics unit is developing NVB302...
...NVB302 , a preclinical lantibiotic, to treat Clostridium difficile infection. Financial terms were not disclosed. Novacta...

...Clostridium difficile infection. Novacta received the first tranche earlier this year (see BioCentury, Jan. 21). Novacta Biosystems Ltd....